Sandipan Datta

Dr. Sandipan Datta

University of California - Daivs
+1
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Mitochondrion
Verified
Journal Article
Closed access
SASonia A. Allen
Sonia A. Allen
SDSandipan Datta
Sandipan Datta
JSJose Sandoval
Jose Sandoval
ATAlexey Tomilov
Alexey Tomilov
TSThomas Kieran Sears
Thomas Kieran Sears
GCGino Cortopassi
Gino Cortopassi


24 November 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JSJose A. Sandoval
Jose A. Sandoval
ATAlexey Tomilov
Alexey Tomilov
SDSandipan Datta
Sandipan Datta
SASonia Allen
Sonia Allen
RORobert O’donnell
Robert O’donnell
GCGino Cortopassi
Gino Cortopassi
Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. Mammalian target of rapamycin Complex 1 (mTORC1) regulates cell proliferation and has been shown by others to have reduced activity in GBMSC. We recently identified a novel chemical series of human-safe piperazine-based brain-penetrant mTORC1-specific inhibitors. We assayed the piperazine-mTOR binding strength by two biophysical measurements, biolayer interferometry and field-effect biosensing, and these confirmed each other and demonstrated a structure–activity relationship. As mTORC1 is altered in human GBMSC, and as mTORC1 inhibitors have been tested in previous GBM clinical trials, we tested the killing potency of the tightest-binding piperazines and observed that these were potent GBMSC killers. GBMSCs are resistant to the standard-of-care temozolomide therapy, but temozolomide supplemented with tight-binding piperazine meclizine and flunarizine greatly enhanced GBMSC death over temozolomide alone. Lastly, we investigated IDH1-mutated GBMSC mutations that are known to affect mitochondrial and mTORC1 metabolism, and the tight-binding meclizine provoked ‘synthetic lethality’ in IDH1-mutant GBMSCs. In other words, IDH1-mutated GBMSC showed greater sensitivity to the coadministration of temozolomide and meclizine. These data tend to support a novel clinical strategy for GBM, i.e., the co-administration of meclizine or flunarizine as adjuvant therapy in the treatment of GBM and IDH1-mutant GBM.

19 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJose Alberto Sandoval
Jose Alberto Sandoval
ATAlexey Tomilov
Alexey Tomilov
SDSandipan Datta
Sandipan Datta
SASonia Allen
Sonia Allen
RORobert O’donnell
Robert O’donnell
GCGino Cortopassi
Gino Cortopassi
Glioblastoma Multiforme (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. mTORC1 regulates cell proliferation and has been shown by others to have reduced activity in GBMSC. We recently identified a novel chemical series of human-safe piperazine-based brain-penetrant mTORC1-specific inhibitors. We assayed piperazine-mTOR binding strength by two biophysical measurements-- biolayer interferometry and field effect biosensing, and these confirmed each other and demonstrated a structure-activity relationship. Since mTORC1 is reduced in human GBMSC, and as mTORC1 inhibitors have been tested in previous GBM clinical trials, we tested the killing potency of the tightest-binding piperazines and observed these were potent GBMSC killers. GBMSCs are resistant to the standard-of-care temozolomide therapy--but temozolomide supplemented with tight-binding piperazine meclizine and flunarizine greatly enhanced GBMSC death over temozolomide alone. Lastly, we investigated IDH1-mutated GBMSC mutations that are known to affect mitochondrial and mTORC1 metabolism, the tight-binding Meclizine provoked ‘synthetic lethality’ in IDH1-mutant GBMSCs. These data tend to support a novel clinical strategy for GBM, i.e. the co-administration of meclizine or flunarizine as adjuvant therapy in the treatment of GBM, and IDH1-mutant GBM.

1 November 2013 in Mitochondrion
Verified
Journal Article
Closed access
SDSandipan Datta
Sandipan Datta
GCGino Cortopassi
Gino Cortopassi